Recent News

• 08.28.2025 - argenx to Present at Upcoming Investor Conferences
• 08.28.2025 - argenx to Present at Upcoming Investor Conferences
• 08.25.2025 - argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG
• 08.25.2025 - argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG
• 08.19.2025 - argenx to Host R&D Webinar Highlighting ARGX-119 on September 16, 2025
• 08.19.2025 - argenx to Host R&D Webinar Highlighting ARGX-119 on September 16, 2025
• 08.12.2025 - argenx and Tennis Legend Monica Seles Team Up to Raise Awareness of Myasthenia Gravis
• 08.12.2025 - argenx and Tennis Legend Monica Seles Team Up to Raise Awareness of Myasthenia Gravis
• 07.31.2025 - argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business Update
• 07.31.2025 - argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business Update

Recent Filings

• 08.25.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 08.25.2025 - EX-99.1 EX-99.1
• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.12.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 07.31.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 07.31.2025 - EX-99.1 EX-99.1